肺鳞癌|一文回顾｜晚期肺鳞癌免疫治疗进展( 三 ) 肺鳞癌|免疫|化疗|替雷利珠单

文章图片

综上所述，近几十年，化学治疗、靶向治疗在肺鳞癌没有明显突破，免疫治疗在肺鳞癌取得了突破性的进展，成为肺鳞癌治疗的一种重要手段，无论一线还是二线，免疫治疗推荐所占比重越来越大，从侧面也反应了免疫治疗是未来肺鳞癌的主要趋势。
参考文献：
[1] Wang J, Lu S, Yu X, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(5):709-717. doi:10.1001/jamaoncol.2021.0366
[2] Zhou C, Ren S, Chen J, et al. 96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial. Journal of Thoracic Oncology, 2021,16( 4).
[3] Zhou C, Wu L, Fan Y, et al. LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC). Annals of Oncology, 2020, 31:S1186.
[4] Jassem J, de Marinis F, Giaccone G, et al. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC [published online ahead of print, 2021 Jul 12]. J Thorac Oncol. 2021; S1556-0864(21) 02286-3. doi:10.1016/j.jtho.2021. 06.019
[5] Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020-2031. doi:10.1056/NEJMoa1910231
[6] Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2021 Mar;22(3):e92]. Lancet Oncol. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0
[7] ZHOU cC. HUANG DZ, YU XM, et al. Results from RATIONALE 303: A global phase 3 study of tislelizumab TIS ws docetaxel (TAX) as second-or tid-line therapy for patients with beally advancedor metastatic NSCLC. Cancer Res, 2021, 81 (13_ Suppl): Abstrat nr CT039.
[8] SHI YK, WU L, YU XM, et al. ORIENT-3: A randomized, open-label, phase 3 study of sintilimabversus docetaxel in previously treated advanced/metastatic squamous non-small-ell lungcancer (sqNSCLC). Cancer Res, 2021, 81 (13_ Suppl): Abstract nr CT041.